未知生产厂商
EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
EHC18 is an oral compound thought to modulate immune responses to HCV by inducing tolerance, or non-responsiveness to viral antigens, thus potentially reducing inflammation.
Investigated for use/treatment in hepatitis (viral, C) and hepatocellular carcinoma.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
